Kyle Matschke

Awards Nomination 20+ Million Readerbase

PMC/PubMed Indexed Articles

Statistical considerations in biosimilar assessment using biosimilarity index

In-vitro Release of Rapamycin from a Thermosensitive Polymer for the Inhibition of Vascular Smooth Muscle Cell Proliferation

Google Scholar citation report

Citations : 4890

Journal of Bioequivalence & Bioavailability received 4890 citations as per Google Scholar report

Journal of Bioequivalence & Bioavailability peer review process verified at publons

25+ Million Website Visitors

Indexed In

Academic Journals Database
Open J Gate
Genamics JournalSeek
Academic Keys
JournalTOCs
China National Knowledge Infrastructure (CNKI)
CiteFactor
Scimago
Ulrich's Periodicals Directory
Electronic Journals Library
RefSeek
Hamdard University
EBSCO A-Z
OCLC- WorldCat
SWB online catalog
Virtual Library of Biology (vifabio)
Publons
MIAR
University Grants Commission
Geneva Foundation for Medical Education and Research
Euro Pub
Google Scholar

Useful Links

Share This Page

Journal Flyer

Journal of Bioequivalence & Bioavailability

Tweets by

Open Access Journals

Kyle Matschke

Pfizer Inc, Collegeville, Pennsylvania, USA

Biography

Kyle Matschke is a researcher in Pfizer Inc, Collegeville, Pennsylvania, USA .Currently his latest research interest is on the field of fixed-dose combination (FDC) product of a selective sodium-glucose cotransporter 2 inhibitor ertugliflozin and immediate-release metformin is approved for type 2 diabetes mellitus in the United States, European Union countries, Canada, and other countries